Article Page

Abstract

A new optimization algorithm for combined processes of deep-drawing and ironing has been created in order to improve these types of axisymmetric components manufacturing procedures. The model provides a comprehensive analysis of those phenomena occurring in multi-stage processes of axisymmetric geometry work-pieces. The scientific development starts out from works that provide LDR (limiting drawing ratio) solutions based on normal anisotropy value, strain hardering exponent and others parameters which have just been applied to the drawing and redrawing stages so far. During embryogenesis, specific proteins expressed in cells have key roles in the formation of differentiated cells and tissues. Delivery of specific proteins into specific cells, both in vitro and in vivo, has proved to be exceedingly difficult. The PLGA NPs were used to deliver proteins into human mesenchymal stem cells (hMSCs). Fluorescent markers loaded into the PLGA NPs were used to verify the internalization of NPs into hMSCs using FACS analysis and confocal microscopy. With these methods, we demonstrated that the encapsulated model proteins are readily delivered into hMSCs, released from the NP vehicles, and, finally, moved into the cytosols. Using chondrogenesis-related proteins such as aggrecan and cartilage oligomeric matrix protein (COMP), chondrogenic differentiation of hMSCs treated with aggrecan and COMP encapsulated PLGA NPs was clearly observed and caused to differentiate into chondrocytes. The authors extend this work to the ironing stages, and also provide a global and integral scientific solution for the whole process. At the beginning the algorithm provides an initial solution which is afterwards optimized by means of objective functions and constraints. The resolution of the optimization process is carried out by a recursive function that minimizes the total time of the global process. The enhanced solution performs a significant reduction in time and costs of the process. The model allows the modification and correction of certain process variables in order to predict the impact of those that are not fully controllable. The final results are compared using experimental results obtained by the authors, so as to show the reliability of the complete solution. In this study, we developed a safe and efficient protein delivery system using An in silico axisymmetric multistage model of linear biphasic mesenchymal stem cell and chondrocyte protein secreted-matrix interactions for the reconstruction of the dynamic mechanical environment of a time varying magnetic field expanded chondrocyte biphasic finite elemental model in articular cartilage for the evaluation of the ability of natural and synthetic scaffolds in providing an appropriate environment for growth and sustain of the chondrogenic capacity of de-differentiated of cartilage-derived L-lactic glycolic acid (PLGA) loaded chondrocytes of proteins into biodegradable poly-(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs).

Article Type

Research Article – Abstract

Publication history

Received: Sep 20, 2017
Accepted: Sep 25, 2017
Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) An in silico axisymmetric multistage model of linear biphasic mesenchymal stem cell and chondrocyte protein secreted-matrix interactions for the reconstruction of the dynamic mechanical environment of a time varying magnetic field expanded chondrocyte biphasic finite elemental model in articular cartilage for the evaluation of the ability of natural and synthetic scaffolds in providing an appropriate environment for growth and sustain of the chondrogenic capacity of de-differentiated of cartilage-derived L-lactic glycolic acid (PLGA) loaded chondrocytes for and then for autologous transplantations.

Authors Info

Grigoriadis Nikolaos
Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis Ioannis
Department of Computer Drug Discovery Science, BiogenetoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis George
Department of Stem Cell Bank and ViroGeneaTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

George Galazios
Professor of Obstetrics and Gynecology,
Democritus University of Thrace,
Komotini, Greece;

E-mail: biogeneadrug@gmail.com

File not available